Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.
about
A Practical Approach to Management of Chronic Hepatitis BKASL clinical practice guidelines: management of chronic hepatitis BManagement of patients with hepatitis B who require immunosuppressive therapyEfficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settingsA new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis BAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNAManagement of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelinesA comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B.A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practiceOutbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010.Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experienceComparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients.Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.Management of hepatitis B in developing countries.Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion.A low proportion of HBeAg among HBsAg-positive pregnant women with known HIV status could suggest low perinatal transmission of HBV in Cameroon.High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study.MicroRNA panels as disease biomarkers distinguishing hepatitis B virus infection caused hepatitis and liver cirrhosis.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.The laboratory diagnosis of hepatitis B virus.A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa.Predicting survival in hepatitis B.Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patientsNew developments in the treatment of chronic hepatitis B.Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.Recommendations and potential future options in the treatment of hepatitis B.Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.Management of patients with HBeAg-negative chronic hepatitis BCorrelation between viral load of HBV in chronic hepatitis B patients and precore and Basal core promoter mutationsMolecular testing in the diagnosis and management of chronic hepatitis BEvaluation of a new hepatitis B virus surface antigen rapid test with improved sensitivity.The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis.Histological grading and staging of liver and its relation to viral loads in chronic anti-HBe positive hepatitis.
P2860
Q24810145-17646336-C0CA-4D61-95F5-87724EBABCE8Q26752475-45C336CC-DE20-4471-808E-FDF1A790C3B8Q26853490-44CD7C26-F8BD-40AE-9211-352CC5B5B25BQ28540372-E2857B82-7FD7-447E-8D80-29AA35947C45Q28741501-5687ED3B-B990-48AA-A599-7FBC083EEF64Q30391932-328603BC-FD8C-45C7-8884-3CDBA8E3CE8DQ33718958-6662C8E8-83AC-4D44-A57B-0C57124A37F2Q33825842-5B4CDAE5-16BE-4654-87E3-837D6C59C178Q33855708-B2DC40FD-BAB1-4CA3-8CA8-A5DE2C23857CQ33959934-ABCF48B6-4B3D-4A7E-AD88-30A6F6C2B0B1Q34137291-42EBF862-9627-4D1A-BAE3-EB9049554B2AQ34173092-084B52EC-89A1-4EA4-AF4C-70084D075FB1Q34184642-96DCA736-1E8B-4D8F-8346-0AB9F4A10151Q34256062-F3908F39-691E-46FF-91A3-5DB30F5954C0Q34539997-4B7CE4BF-4CEC-47AD-A25D-DBBDFB05A9C2Q34683065-9BB711B8-0E0A-4086-9071-CB8F21B39396Q35495205-86CD1210-46BD-439A-A9DE-15A36E98663EQ35589366-A812EBC5-EB67-46CA-A7B2-705B1007385DQ35596851-6BD74060-22E7-4F29-87F9-83EC730F5718Q35597930-829C019B-8667-47F8-965B-3E73962BB643Q35635637-43108A53-AABA-4569-8D3F-A691FBA8CCF9Q35840358-BF4EA9B4-4E83-43EF-8B17-42213EEA994CQ35861676-E78BA6C3-6AA8-4EED-A064-6F8A1B0A7CDCQ35950941-9226F915-095A-4DA8-9F4B-0BFB4CACE7A1Q36146616-753610B5-01A9-455E-9DFB-FEA5F8EE5C86Q36153966-A6C21DEB-9765-4AD7-9A7C-122C214D4F6AQ36171000-BB91BC18-4F42-4B61-B620-BE7B7AA18904Q36184624-F14A59D4-635E-4142-9A47-E8D4BF866286Q36287594-670B9BDA-84CD-4359-95A5-8AF30BFFD6DBQ36391991-485A3FB5-125F-474C-9A65-B1C14E18FAFFQ36569744-CC6405C7-4B9C-448D-A496-3ADC714FFF27Q36573919-26F71EC8-680B-4784-B86C-7B3B03BB9D75Q36632233-3166EF92-53BD-4A55-ACDE-CECB5D4E97CFQ36724380-1E3596FD-A5A0-4944-B823-96DCD0622C8EQ36724421-B4A3E3BD-F957-4CF1-8CC7-9D9FC11170BDQ36771263-FB804FAD-8C27-4D56-8DE2-3AE21C894A42Q36881140-6D5FB7AF-4202-4661-A85F-6B59AD44624FQ36933452-09B07B2C-FB15-45EC-8546-A74FFB89D3AEQ37111755-77083634-3755-436C-B383-465C986D6DCEQ37128478-F222B2BF-B67A-4D79-BB99-9720EC5F0960
P2860
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@en
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@nl
type
label
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@en
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@nl
prefLabel
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@en
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@nl
P2093
P356
P1433
P1476
Quantitative serum HBV DNA lev ...... chronic hepatitis B infection.
@en
P2093
Anna S F Lok
Chi-Jen Chu
Munira Hussain
P304
P356
10.1002/HEP.1840360617
P407
P577
2002-12-01T00:00:00Z